issues within maintenance therapy standardization in mm
Published 4 years ago • 144 plays • Length 3:31Download video MP4
Download video MP3
Similar videos
-
1:48
do all patients require maintenance therapy following allosct?
-
1:44
improving maintenance therapy in aml: exploring the role of idh inhibitors
-
3:47
why maintenance therapy in aml is unnecessary
-
2:03
maintenance therapy in aml
-
1:59
topics of interest in mds: the role of maintenance therapy, immune checkpoints & ven-aza in hr-mds
-
2:49
maintenance therapy in aml: agents under investigation and future outlooks
-
2:42
optimizing maintenance therapy in multiple myeloma: an analysis from the preamble registry
-
3:52
maintenance therapy with revumenib following allosct in kmt2ar and npm1-mutated acute leukemias
-
3:02
the effects of maintenance therapy on real-world outcomes for patients with ndmm
-
3:10
should maintenance therapy after autograft be limited?
-
14:43
current research into post-allosct maintenance therapy in aml
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
2:12
barriers to the implementation and standardization of ai in the clinic
-
5:34
updates on maintenance therapies in aml
-
1:11
the treatment of aml within the united kingdom nhs framework
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
1:02
maintenance therapy following treatment for amyloidosis
-
1:33
tourmaline-mm3: undetectable mrd as an endpoint for maintenance therapy